Ofatumumab – B Cell Therapy
Serum Neurofilament Light Chain Levels and NEDA-3 Status With Ofatumumab Treatment in Diverse Racial/Ethnic Subgroups With Relapsing Multiple Sclerosis: 5-Year Results From ALITHIOS
Alvarez E et al
Poster: LB14
Poster: LB14
Longer-term (up to 6 years) Efficacy of Ofatumumab in People With Recently Diagnosed and Treatment-Naïve Relapsing Multiple Sclerosis
Pardo G et al
Poster: DMT20
Poster: DMT20
Longer-term Safety and Efficacy of Ofatumumab in People With Relapsing Multiple Sclerosis for up to 6 years
Wiendl H et al
Poster: DMT26
Poster: DMT26
Cumulative Pregnancy Outcomes in Patients With Multiple Sclerosis Following Maternal Exposure to Ofatumumab: Results From the Novartis Safety Database
Bove R et al
Poster: DMT45
Poster: DMT45
B-Cell Depletion and Efficacy Outcomes of Ofatumumab are Consistent Across Different Body Mass Index Categories: Insights From the ASCLEPIOS I/II Trials
Cross AH et al
Poster: DMT43
Poster: DMT43
Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials
Delgado SR et al
Poster: NIB09
Poster: NIB09
Ofatumumab Reduces Clinical and Radiological Activity in People With Recently Diagnosed Treatment-Naïve RMS Irrespective of Baseline sNfL Levels
Pardo G et al
Poster: DMT22
Poster: DMT22
Change in Healthcare Resource Utilization Following Initiation of Ofatumumab in Patients With Multiple Sclerosis
Tai MH et al
Poster: DMT39
Poster: DMT39
Real-world Persistence and Adherence to Ofatumumab vs Ocrelizumab in Patients With Multiple Sclerosis
Tai MH et al
Poster: DMT38
Poster: DMT38
Remibrutinib – BTK Inhibitor
Remibrutinib, a Highly Selective and Potent BTKi in Development for MS, Did Not Impact Serum Immunoglobulin Levels: Insights From Chronic Spontaneous Urticaria
Bermel R et al
Poster: DMT53
Poster: DMT53
HEOR
Travel Burden for Patients With Multiple Sclerosis Treated With Infusible Disease Modifying Therapies
Tai MH et al
Poster: DMT37
Poster: DMT37
MLR ID: 444613